Cryptococcus gattii Meningoencephalitis in an Immunocompetent Person 13 Months after Exposure by Georgi, A. et al.
Cryptococcus gattii Meningoencephalitis
in an Immunocompetent Person
13 Months after Exposure
A. Georgi, M. Schneemann, K. Tintelnot, R.C. Calligaris-Maibach,
S. Meyer, R. Weber, P.P. Bosshard
Abstract
A 53-year old immunocompetent Swiss female is described
who developed severe meningoencephalitis due to infection
with Cryptococcus gattii 13 months following exposure on
Vancouver Island, Canada. Diagnosis was based on cerebro-
spinal fluid (CSF) examination, i.e., positive India-ink stain-
ing, positive latex particle agglutination, and positive culture.
Species identification was performed by growth on L-cana-
vanine–glycine–bromthymol blue medium and by sequencing
of the intergenic and internal transcribed spacer regions of the
rRNA genes. After initial therapy with fluconazole by which
the patient did not improve, therapy was changed to
amphotericin B and flucytosine and later to high-dose
fluconazole and amphotericin B. Despite long-term treatment
and external drainage of the CSF, the patient’s condition
improved only slowly. The patient was discharged after
132 days of hospitalization.
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Introduction
The etiologic agent of cryptococcosis is classified into two
species: Cryptococcus neoformans (serotype A, AD and
D) and Cryptococcus gattii (serotype B and C; formerly
C. neoformans var. gattii) [1]. Both are encapsulated
environmental yeasts which, however, differ in their
natural habitat and geographical distribution. In nature,
C. neoformans has been isolated all over the world from
soil contaminated with pigeon or other bird droppings.
C. gattii has been isolated from decaying wood, mainly of
Eucalyptus trees, with the distribution of human infections
corresponding in general to the distribution of these trees,
i.e., tropical and subtropical areas such as Australia,
Central and South America, India, China, and limited
areas in Europe [2]. However, in 1999, a C. gattii outbreak
emerged on Vancouver Island, Canada [3].
C. neoformans tends to infect – although not exclu-
sively – immunodeficient people, such as HIV-infected
individuals and those with lymphoproliferative disorders
or on corticosteroid treatment. Infection typically mani-
fests as diffuse meningitis or meningoencephalitis. In
contrast, C. gattii preferably infects immunocompetent
hosts, with the major risk factor appearing to be environ-
mental exposure [4]. In C. gattii infection, cerebral mass
lesions and/or hydrocephalus, pulmonary mass lesions,
increased neurological deficits, and a slower response
to treatment are more common than in C. neoformans
infection [4].
Case Report
A 53-year-old woman with no relevant prior medical
history was admitted to hospital in October 2006 because
of fever and persistent headache for 1 month, walking
disturbances, and vision disorder. During the physical
examination, she suffered a partial epileptic seizure. A CT
scan of the brain was normal, but the pressure of the CSF
was markedly elevated (46 cm H2O). Analyses of the CSF
showed a cell count of 100 ll–1, increased protein (1.5 g/l),
and reduced glucose. Empiric intravenous antimicrobial
therapy with ceftriaxon, amoxicillin, and acyclovir was
started (Figure 1). The CSF was subsequently reported to
be positive for cryptococcal antigen (Meridian Diagnos-
tics, Cincinnati, OH) (titer > 1:2,048; Figure 1). Staining
of the CSF with India ink (or with periodic acid-Schiff
reagent) showed abundant encapsulated yeast cells upon
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microscopic evaluation. Intravenous antibiotics were
stopped and oral therapy with fluconazole (400 mg/day)
was started. Fluconazole was chosen as the initial therapy
because the patient appeared not to be severely ill at this
time. The yeast cells of the CSF culture were biochemi-
cally identified with the Auxacolor system (Sanofi Diag-
nostics Pasteur, Freiburg, Germay) as Cryptococcus
neoformans. Based on the ability of the cells to grow on
CGB medium and on sequence analysis of the intergenic
spacer 1 region (IGS1), we identified the isolate as
C. gattii [5]. The IGS sequence was assigned to the IGS
genotype 3 [6]. The isolate was serotyped by Crypto-
Check (Iatron Laboratories, Tokyo, Japan) as serotype B,
and this identification was confirmed by Fourier transform
infrared (FT-IR) spectroscopy [7]. Sequence analysis of
the internal transcribed spacer (ITS) regions revealed that
the isolate belonged to the ITS type 4 according to Katsu
et al. [8], which correlates to the genotype VGII [8, 9].
Susceptibility testing was performed using the Sensititre
YeastOne plate (Trek Diagnostics Systems, East Grin-
stead, UK). The results were as follows (in lg/ml):
amphotericin B, 0.5; flucytosine, 2.0; fluconazole, 8.0;
itraconazole, 0.064, ketokonazole, 0.032; voriconazole,
0.064.
Due to clinical deterioration of the patient, after 18
days we switched the oral regimen to amphotericin B iv
(1 mg/kg of body weight = 60 mg/day) and flucytosine
(4 · 2.25 g/day). Repeated testing for HIV produced
negative results. An external ventricular drainage was
placed to decrease the persistently elevated intracranial
pressure (Figure 1). Once a substantial improvement in
clinical condition had been achieved, after 2 months, the
external ventricular shunt was removed, and drug therapy
was changed back to oral fluconazole (800 mg/day). The
cryptococcal CSF antigen titer had decreased to 1:32,
while the serum antigen titer was still 1:1,024. A week
later, the patient complained of headaches again and
became confused. The cryptococcal antigen titer in the
CSF had increased from 1:32 to 1:512, the protein was
highly elevated, and glucose was non-detectable. Therapy
with amphotericin B iv (60 mg/day) was resumed for
2 weeks and the dose of oral fluconazole was augmented
(2 · 800 mg/day). A new external shunt was put in place
for an additional month. The high dose of fluconazole
being administered caused the patient’s steroid synthesis
to be blocked, and she developed symptoms and signs of
hypocorticism (hypotonia, hypoglycaemia, dark staining
of the skin). This resolved when a substitution with cor-
ticosteroids (hydrocortisone 100 mg/day) was started. At
the time of discharge, after 132 days of hospitalization, the
patient was taking fluconazole 600 mg/day and cortico-
steroids (hydrocortisone 75 mg/day). Her only manifes-
tation was a slight tremor and she had no further
neurological deficits; the cryptococcal antigen titer in the
serum was 1:256. The shunt had been removed 5 weeks
prior to discharge, and no further measurement of CSF
pressure had taken place.
At the last visit as an outpatient in May 2008 the
patient was doing well without any neurologic impairment
or headache. She has restarted working for 3 h four times
a week. The serum antigen titer was 1:8. She is still taking
oral fluconazole at a dose of 600 mg/day (400 mg in the
morning, and 200 mg in the evening).
Discussion
Most C. gattii infections in humans have been reported
from tropical and subtropical areas, mainly Australia and
the South Pacific but also Cambodia, Latin America, the
USA, and Sub-Saharian Africa [4, 5]. Only a few infec-
tions have been reported from countries with a moderate-
temperate climate. In 1999, a C. gattii outbreak emerged
on Vancouver Island, Canada [3]. Although rare autoch-
thonous infections due to C. gattii in Europe have been
reported [2, 10–12], most infections in European residents
were acquired outside Europe. The sequence of both the
ITS regions and the IGS1 region of the cryptococcal iso-
late obtained from our patient was found to be identical
with those of the genotype VGII isolates which caused
the Vancouver Island outbreak [8, 9, 13]. Thus, it is likely
that she acquired her infection while visiting Vancouver
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Island in August 2005, 13 months prior to the onset of
symptoms. Earlier cases of C. gattii infection in travelers
to Vancouver Island have shown that the incubation
periods of C. gattii infection range from 2 to 11 months
[14]. This case demonstrates that a careful travel history
in which the itineraries of past holidays and journeys to
non-tropical regions should be included in the medical
history.
The cryptococcal antigen test for sera and CSF is an
easy-to-perform and highly sensitive diagnostic test for
cryptococcosis. However, the clinician has to be aware of
the fact that, in rare instances, immunocompetent pa-
tients can also suffer from cryptococcosis and therefore
request the test when this infection is suspected. The
antigen test is not able to identify the etiologic agent at
the species level. The correct species assignment of
cryptococcal isolates in apparently immunocompetent
patients, however, is important, not only for epidemio-
logical reasons, but also for prognosis and eventual
treatment duration. C. gattii infections tend to follow a
more chronic course in immunocompetent people than
infections with C. neoformans [4], and a slower response
and worse prognosis have been noted with the former
[4, 15]. Identification in countries with a low prevalence
of C. gattii mainly relies on biochemical methods, such as
the Auxacolor (Sanofi Diagnostics Pasteur) or the ID32C
(Biome´rieux, Brussels, Belgium) systems. These routine
diagnostic procedures, however, do not allow C. gattii to
be distinguished from C. neoformans. Additional efforts
are required for assigning an isolate to C. gattii, such as
growth on CGB medium, D-Prolin assimilation, and IGS-
and ITS-sequencing.
In terms of antifungal therapy, the combination of
amphotericin and flucytosine is accepted as being the
most rapid fungicidal therapeutic regimen in the initial
2 weeks of treatment [16]. The goal is to achieve sterili-
zation of the CSF. According to the ‘‘practice guidelines
for the management of cryptococcal disease’’ [17],
immunocompetent hosts with CNS infection should be
treated for 6–10 weeks with amphotericin B iv (0.7–1 mg/
kg daily) and flucytosine iv (100 mg/kg daily) or with
amphotericin B and flucytosine iv (same concentrations)
followed by oral fluconazole at a dose of 400 mg/d for a
minimum of another 10 weeks. After that, a fluconazole
consolidation therapy for another 6–12 months should be
considered, but data are lacking. Recommendations are
extrapolated from the treatment experience of HIV-po-
sitive patients with C. neoformans meningitis. In retro-
spect, the initial treatment of this patient was incorrect,
erroneously based on the appearance of the patient, who
did not seem to be severely ill at the time of presentation.
Species identification was obtained only during the course
of care.
Little is known on the management of increased CSF
pressure. Current recommendations are based on a few
case reports, one small series, and expert opinion [18].
Clinical observations have revealed that patients infected
with C. gattii have a higher rate of hydrocephalus
requiring shunting [18]. The mechanism is hypothesized to
be the obstruction of CSF outflow by to a large burden of
yeasts and polysaccharide plugging the arachnoid granu-
lations. The clinician can either perform daily serial
lumbar punctures or insert a temporary lumbar drain [19,
20]. If patients present with classical obstructive hydro-
cephalus, neurosurgical shunting can improve neurologi-
cal outcome [18]. Aggressive management of elevated
intracranial pressure, with repeated lumbar punctures or
drainage, is one of the most important approaches in
reducing mortality and minimizing morbidity in patients
with cryptococcal meningitis. Medical approaches for the
management of elevated intracranial pressure, such as the
use of corticosteroids or acetazolamid, have not been
found to be effective.
In conclusion, the differential diagnosis of crypto-
coccal meningoencephalitis also needs to be considered in
immunocompetent hosts, particularly in the case of neg-
ative bacterial and virological findings. In such cases, C.
gattii should be considered as the etiologic agent, and
correct species assignment should be attempted with
additional phenotypical and molecular techniques, such as
IGS-sequencing and ITS-subtyping. The case presented
here demonstrates the importance of a carefully taken
travel history.
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